HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells

Blood

Volumn 96, Issue 10, 2000, Pages 3553-3559

  Ikezoe, T ^a   Daar, E S ^a   Hisatake, J I ^a   Taguchi, H ^a   Koeffler, H P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CD11B ANTIGEN; CYTOCHROME P450; GLYCOPROTEIN P; INDINAVIR; MEMBRANE ANTIGEN; PROTEINASE INHIBITOR; RETINOIC ACID; RETINOIC ACID BINDING PROTEIN; RETINOID; RITONAVIR; SAQUINAVIR;

ADJUVANT THERAPY; ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LEUKEMIA CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL;

EID: 0034669985     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.10.3553.h8003553_3553_3559     Document Type: Article

References (59)

1. Induction of differentiation of human acute myelogenous leukemia cells: Therapeutic implication
2. Alltrans-retinoic acid in acute promyelocytic leukemia
3. Use of alltrans retinoic acid in the treatment of acute promyelocytic leukemia
4. Retinoic acid therapy for acute promyelocytic leukemia
5. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid 'resistance' in patients with acute promyelocytic leukemia
6. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells
7. Alltrans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results
8. Differentiation therapy of acute promyelocytic leukemia with retinoin (all-trans retinoic acid)
9. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia
10. Metabolism of retinoic acid: Implications for development and cancer
11. Retinoic acid biosynthesis and metabolism
12. Structure/function of cytoplasmic vitamin A-binding proteins
13. A decade of molecular biology of retinoic acid receptors
14. Molecular cloning of two human cellular retinoic acid-binding proteins (CRABP)
15. Induction of retionoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients
16. Structure of the human cellular retinoic acid-binding protein II gene
17. Molecular cloning of cDNA encoding a second cellular retinoic acid binding protein
18. Retinoic acid induction of human cellular retinoic acid-binding protein II gene transcription is mediated by retinoic acid receptorretinoid X receptor heterodimers bound to one far upstream retinoic acid-responsive element with 5-base pair spacing
19. Localization of CRABP-I and CRABP-II mRNA in the early mouse embryo by whole-mount in situ hybridization: Implications for teratogenesis and neural development
20. Mechanisms of retinoid resistance in leukemic cells: Possible role of cytochrome P450 and P-glycoprotein
21. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy
22. Retinoic acid-resistant HL-60 cells harbor a point mutation in the retinoic acid receptor ligand binding domain that confers dominant negative activity
23. Retinoic acid resistant HL-60 cells exclusively contain mutant retinoic acid receptor α
24. A retinoic acid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation
25. HIV-protease inhibitors
26. HIV-1 protease inhibitors
27. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitorassociated lipodystrophy, hyperlipidemia, and diebetes mellitus: A cohort study
28. Indinavir-associate lipodystrophy
29. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
30. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
31. Pathogenesis of HIV-protease inhibitors-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance
32. Cytchrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes
33. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
34. Induction of differentiation of the human myelocytic leukemia cell line (HL-60) by retinoic acid
35. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3)
36. Establishment and characterization of a novel acute promyelocytic cell line (UF-1) with retinoic acid-resistant features
37. Novel retinoic acid, 9-cis-retinoic acid, in combination with alltrans retinoic acid is an effective inducer of differentiation of retinoic acid-resistant HL-60 cells
38. CCAAT/enhancer binding protein ε is a potential retinoid target gene in acute promyelocytic leukemia treatment
39. Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide
40. Cloning of the novel human myeloid-cell-specific C/EBP epsilon transcription factor
41. Modulation of mRNA expression of a novel human myeloid-selective CCAAT/enhancer binding protein gene (C/EBPε)
42. Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice
43. Stimulation of vitamin A (1) acid signaling by the HIV protease inhibitor indinavir
44. Metabolism of all-trans retinoic acid in hamster liver microsomes: Oxidation of 4-hydroxy-to 4-keto retinoic acid
45. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes
46. The cloning and characterization of a novel cytochrome P450 family, CYP26, with specificity toward retinoic acid
47. In vitro metabolism of retinoic acid in hamster intestine and liver
48. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
49. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
50. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir
51. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
52. Genetic analysis of the multidrug transporter
53. Retinoid resistance in leukemic cells
54. Restoration of retinoid sensitivity by MDR1 ribozymes in retinoic acid-resistant myeloid leukemic cells
55. Development of extended multidrug resistance in HL60 promyelocytic leukaemia cells
56. Frequency and clinical Significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
57. Acute intoxication with verapamil
58. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
59. A novel human CCAAT/enhancer binding protein gene, C/EBPε, is expressed in cells of lymphoid and myeloid lineages and is localized on chromosome 14q11.2 close to the T-cell receptor α/δ locus